In a nutshell This study aimed to investigate the outcomes of standard adjuvant chemotherapy versus capecitabine (Xeloda) in older patients with breast cancer after 10 years. This study concluded that with longer follow up, outcomes remained superior with standard adjuvant chemotherapy. Some...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read More
In a nutshell This study investigated the effectiveness of alpelisib (Piqray) in hormone receptor-positive (HR+) -human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). They found that alpelisib significantly improved survival in patients with PIK3CA mutations. Some background Breast cancer (BC) types can be...
Read More
In a nutshell This study investigated if a combination including pertuzumab (Perjeta) and subcutaneous trastuzumab (Herceptin Hylecta) is safe in breast cancer (BC). They found that this combination was well tolerated in patients with HER2-positive BC. Some background Breast cancer (BC) is the most common cancer in...
Read More
In a nutshell This study investigated the risk of fatigue and anemia with olaparib (Lynparza) treatment. The study found that there is an increased risk of fatigue and anemia with this treatment. Some background Breast cancer (BC) is the most common cancer affecting women. Some types of BC are caused by genetic mutations. These...
Read MoreIn a nutshell This phase 1b/2 trial will investigate the safety of treatment with rucaparib (Rubraca) in combination with other anti-cancer agents (ACAs) in patients with triple-negative breast cancer and other solid tumors. The main outcomes will be the number of treatment-related side effects and response to treatment. This trial is...
Read More
In a nutshell This phase 2 trial will investigate the effects of tesetaxel combined with targeted therapy drugs in advanced breast cancer (BC). The main outcomes will be the overall response rate (ORR) and progression-free survival (PFS). This trial is recruiting in Boston, MA and East Setauket, NY. The details Some...
Read More
In a nutshell This phase 2 trial will investigate the effects of tesetaxel combined with targeted therapy drugs in advanced breast cancer (BC). The main outcomes will be the overall response rate (ORR) and progression-free survival (PFS). This trial is recruiting in Boston, MA and East Setauket, NY. The details Some...
Read More
In a nutshell This study investigated female fertility preservation (FFP) in cancer patients. They found that FFP should be discussed with all women of reproductive age undergoing cancer treatment. Some background Cancer can have many negative effects on patient health. Infertility is a particular concern for younger female patients. Pregnancy...
Read MoreIn a nutshell This phase 3 trial will investigate the effect of bupropion (Wellbutrin) to treat fatigue in patients with breast cancer (BC). The main outcomes will be fatigue, quality of life and depression. This trial is recruiting across the United States. The details After treatment for breast cancer (BC), many women report feeling...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this....
Read More
In a nutshell This study wanted to find out how well patients with hormone-receptor-positive breast cancer survived when treated with ribociclib (Kisqali) added to endocrine therapy. The study found that patients treated with this treatment combination had longer survival compared to endocrine therapy alone. Some background Advanced breast cancer can...
Read More
